LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice

Journal of Neuroinflammation

Volumn 7, Issue , 2010, Pages

  Lee, Daniel C ^a   Rizer, Justin ^a   Selenica, Maj Linda B ^a   Reid, Patrick ^a   Kraft, Clara ^a   Johnson, Amelia ^a   Blair, Laura ^a   Gordon, Marcia N ^a   Dickey, Chad A ^a   Morgan, Dave ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; CD45 ANTIGEN; LECTIN; LIPOPOLYSACCHARIDE; SERINE; TAU PROTEIN; UNCLASSIFIED DRUG; YM 1 PROTEIN;

AGE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; FRONTAL CORTEX; GENE MUTATION; HIPPOCAMPUS; INFLAMMATORY DISEASE; MALE; MICROGLIA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SILVER STAINING; TAUOPATHY; TRANSGENIC MOUSE; ANALYSIS OF VARIANCE; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ENCEPHALITIS; FRONTAL LOBE; IMMUNOHISTOCHEMISTRY; METABOLISM; NERVE CELL; NEUROFIBRILLARY TANGLE; PATHOLOGY; PHOSPHORYLATION;

AGE FACTORS; ANALYSIS OF VARIANCE; ANIMALS; ENCEPHALITIS; FRONTAL LOBE; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; LIPOPOLYSACCHARIDES; MICE; MICE, TRANSGENIC; MICROGLIA; NEUROFIBRILLARY TANGLES; NEURONS; PHOSPHORYLATION; SILVER STAINING; TAU PROTEINS;

EID: 77956592281     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-7-56     Document Type: Article

References (39)

1. Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, Wszolek Z, Ashe K, Knight J, Dickson D, et al. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 2007, 27:3650-3662. 10.1523/JNEUROSCI.0587-07.2007, 17409229.
2. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 2000, 25:402-405. 10.1038/78078, 10932182.
3. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005, 309:476-481. 10.1126/science.1113694, 1574647, 16020737.
4. Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, Guimaraes A, Yue M, Lewis J, Carlson G, et al. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci 2005, 25:10637-10647. 10.1523/JNEUROSCI.3279-05.2005, 16291936.
5. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L, LaFrancois J, Feinstein B, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 2005, 102:6990-6995. 10.1073/pnas.0500466102, 1088065, 15867159.
6. Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, Greengard P, Biernat J, Wu YZ, Mandelkow EM, et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?. J Biol Chem 2001, 276:251-260. 10.1074/jbc.M002466200, 11013232.
7. Jope RS. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 2003, 24:441-443. 10.1016/S0165-6147(03)00206-2, 12967765.
8. Sereno L, Coma M, Rodriguez M, Sanchez-Ferrer P, Sanchez MB, Gich I, Agullo JM, Perez M, Avila J, Guardia-Laguarta C, et al. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol Dis 2009, 35:359-367. 10.1016/j.nbd.2009.05.025, 19523516.
9. Jinwal UK, Miyata Y, Koren J, Jones JR, Trotter JH, Chang L, O'Leary J, Morgan D, Lee DC, Shults CL, et al. Chemical manipulation of hsp70 ATPase activity regulates tau stability. J Neurosci 2009, 29:12079-12088. 10.1523/JNEUROSCI.3345-09.2009, 2775811, 19793966.
10. Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J, Ash P, Shoraka S, Zlatkovic J, Eckman CB, et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest 2007, 117:648-658. 10.1172/JCI29715, 1794119, 17304350.
11. Dickey CA, Dunmore J, Lu B, Wang JW, Lee WC, Kamal A, Burrows F, Eckman C, Hutton M, Petrucelli L. HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J 2006, 20:753-755.
12. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004, 43:321-332. 10.1016/j.neuron.2004.07.003, 15294141.
13. Wilcock DM, Gharkholonarehe N, Van Nostrand WE, Davis J, Vitek MP, Colton CA. Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease. J Neurosci 2009, 29:7957-7965. 10.1523/JNEUROSCI.1339-09.2009, 2871319, 19553436.
14. Mastrangelo MA, Sudol KL, Narrow WC, Bowers WJ. Interferon-{gamma} differentially affects Alzheimer's disease pathologies and induces neurogenesis in triple transgenic-AD mice. Am J Pathol 2009, 175:2076-2088. 10.2353/ajpath.2009.090059, 19808651.
15. Zilka N, Stozicka Z, Kovac A, Pilipcinec E, Bugos O, Novak M. Human misfolded truncated tau protein promotes activation of microglia and leukocyte infiltration in the transgenic rat model of tauopathy. J Neuroimmunol 2009, 209:16-25. 10.1016/j.jneuroim.2009.01.013, 19232747.
16. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci 2005, 25:8843-8853. 10.1523/JNEUROSCI.2868-05.2005, 16192374.
17. Li Y, Liu L, Barger SW, Griffin WS. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci 2003, 23:1605-1611.
18. Cameron B, Landreth GE. Inflammation, microglia, and Alzheimer's disease. Neurobiol Dis 2009, 37:503-509. 10.1016/j.nbd.2009.10.006, 19833208.
19. Colton CA, Mott RT, Sharpe H, Xu Q, Van Nostrand WE, Vitek MP. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J Neuroinflammation 2006, 3:27. 10.1186/1742-2094-3-27, 1609108, 17005052.
20. Jimenez S, Baglietto-Vargas D, Caballero C, Moreno-Gonzalez I, Torres M, Sanchez-Varo R, Ruano D, Vizuete M, Gutierrez A, Vitorica J. Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer's disease: age-dependent switch in the microglial phenotype from alternative to classic. J Neurosci 2008, 28:11650-11661. 10.1523/JNEUROSCI.3024-08.2008, 18987201.
21. Quinn J, Montine T, Morrow J, Woodward WR, Kulhanek D, Eckenstein F. Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. J Neuroimmunol 2003, 137:32-41. 10.1016/S0165-5728(03)00037-7, 12667645.
22. Malm TM, Koistinaho M, Parepalo M, Vatanen T, Ooka A, Karlsson S, Koistinaho J. Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol Dis 2005, 18:134-142. 10.1016/j.nbd.2004.09.009, 15649704.
23. Herber DL, Mercer M, Roth LM, Symmonds K, Maloney J, Wilson N, Freeman MJ, Morgan D, Gordon MN. Microglial activation is required for Abeta clearance after intracranial injection of lipopolysaccharide in APP transgenic mice. J Neuroimmune Pharmacol 2007, 2:222-231. 10.1007/s11481-007-9069-z, 18040847.
24. Herber DL, Roth LM, Wilson D, Wilson N, Mason JE, Morgan D, Gordon MN. Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Exp Neurol 2004, 190:245-253. 10.1016/j.expneurol.2004.07.007, 15473997.
25. DiCarlo G, Wilcock D, Henderson D, Gordon M, Morgan D. Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice. Neurobiol Aging 2001, 22:1007-1012. 10.1016/S0197-4580(01)00292-5, 11755009.
26. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007, 13:1359-1362. 10.1038/nm1653, 17934472.
27. Spires TL, Orne JD, SantaCruz K, Pitstick R, Carlson GA, Ashe KH, Hyman BT. Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am J Pathol 2006, 168:1598-1607. 10.2353/ajpath.2006.050840, 1606598, 16651626.
28. Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, Connor K, Melachrino J, O'Callaghan JP, Morgan D. Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol 2002, 173:183-195. 10.1006/exnr.2001.7754, 11822882.
29. Morris SM, Kepka-Lenhart D, Chen LC. Differential regulation of arginases and inducible nitric oxide synthase in murine macrophage cells. Am J Physiol 1998, 275:E740-747.
30. Dickey C, Kraft C, Jinwal U, Koren J, Johnson A, Anderson L, Lebson L, Lee D, Dickson D, de Silva R, et al. Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy. Am J Pathol 2009, 174:228-238. 10.2353/ajpath.2009.080764, 2631335, 19074615.
31. Rosi S, Ramirez-Amaya V, Vazdarjanova A, Worley PF, Barnes CA, Wenk GL. Neuroinflammation alters the hippocampal pattern of behaviorally induced Arc expression. J Neurosci 2005, 25:723-731. 10.1523/JNEUROSCI.4469-04.2005, 15659610.
32. Hung SI, Chang AC, Kato I, Chang NC. Transient expression of Ym1, a heparin-binding lectin, during developmental hematopoiesis and inflammation. J Leukoc Biol 2002, 72:72-82.
33. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009, 27:451-483. 10.1146/annurev.immunol.021908.132532, 19105661.
34. Sun YJ, Chang NC, Hung SI, Chang AC, Chou CC, Hsiao CD. The crystal structure of a novel mammalian lectin, Ym1, suggests a saccharide binding site. J Biol Chem 2001, 276:17507-17514. 10.1074/jbc.M010416200, 11278670.
35. Goedert M, Jakes R, Spillantini MG, Hasegawa M, Smith MJ, Crowther RA. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 1996, 383:550-553. 10.1038/383550a0, 8849730.
36. Janelsins MC, Mastrangelo MA, Park KM, Sudol KL, Narrow WC, Oddo S, LaFerla FM, Callahan LM, Federoff HJ, Bowers WJ. Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am J Pathol 2008, 173:1768-1782. 10.2353/ajpath.2008.080528, 2626388, 18974297.
37. McKee AC, Carreras I, Hossain L, Ryu H, Klein WL, Oddo S, LaFerla FM, Jenkins BG, Kowall NW, Dedeoglu A. Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res 2008, 1207:225-236. 10.1016/j.brainres.2008.01.095, 2587244, 18374906.
38. Shaftel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE, O'Banion MK. Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest 2007, 117:1595-1604. 10.1172/JCI31450, 1878531, 17549256.
39. Chakrabarty P, Jansen-West K, Beccard A, Ceballos-Diaz C, Levites Y, Verbeeck C, Zubair AC, Dickson D, Golde TE, Das P. Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J 2009, 24:548-559. 10.1096/fj.09-141754, 19825975.